SCHEMBL4637752

SCHEMBL4637752

CCOC(=O)c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 8/20 0.74
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
ALDH1A1 P00352 4/20 0.48
GAA P10253 2/20 0.48
POLB P06746 3/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48
TSHR P16473 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 3/20 0.45
TP53 P04637 1/20 0.44
ALOX12 P18054 1/20 0.44
MAPT P10636 1/20 0.43
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4639420 0.91 CYP19A1 (0.60) CYP19A1CYP3A4POLBTSHRMEN1
SCHEMBL4707976 0.89 CYP19A1 (0.57) CYP19A1CYP1A2ALDH1A1GAAPOLB
SCHEMBL4637833 0.89 CYP19A1 (0.59) CYP19A1ALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL5797387 0.86 CYP19A1 (0.57) CYP19A1ALDH1A1GAAPOLBMAPK1
SCHEMBL4638473 0.86 ALDH1A1 (0.65) CYP19A1CYP2C9ALDH1A1GAAPOLB
SCHEMBL4706776 0.85 ALDH1A1 (0.54) CYP19A1CYP2C9ALDH1A1GAAPOLB
SCHEMBL6071984 0.84 CYP19A1 (0.52) CYP19A1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL4637748 0.83 CYP19A1 (0.48) CYP19A1ALDH1A1HPGDMEN1KMT2A
SCHEMBL4637791 0.82 CYP19A1 (0.47) CYP19A1ALDH1A1TSHRMEN1KMT2A
SCHEMBL4638842 0.82 CYP19A1 (0.48) CYP19A1ALDH1A1GAAPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501808-B1 TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-07-02 EP disclosed
US-7320994-B2 Triazole derivatives as tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2008-01-22 US disclosed
EP-1501809-B1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-01-16 EP disclosed
US-7179804-B2 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2007-02-20 US disclosed
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists ELI LILLY COMPANY (US) 2005-10-27 US disclosed
US-20050239776-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 2005-10-27 US disclosed
EP-1501809-A1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
EP-1501808-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-02-02 EP disclosed
WO-2003091227-A1 TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed
WO-2003091226-A1 TRIAZOLE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239786-A1 Triazole derivatives as tachykinin receptor antagonists TACR1, TACR2, BDKRB1 CYP19A1 2876/4885CYP1A2 2348/4885CYP3A4 1047/4885
US-20050239776-A1 Tachykinin receptor antagonists TACR2, TACR1, PROKR1 CYP19A1 2765/4885CYP1A2 3148/4885CYP3A4 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.